Navigation Links
EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
Date:7/5/2011

In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

Erlotinib is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). Non-small cell lung cancer (NSCLC) patients with EGFR activating mutations tend to respond well to TKI therapy.

"Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to NSCLC therapy compared to Western populations," said principal investigator Dr. Radj Gervais, M.D., of the Centre Franois Baclesse in Caen, France. "EURTAC is the first Phase III study with first-line erlotinib in Western patients with this genetically distinct type of advanced NSCLC."

Researchers tested more than 1,000 patients over a five-year-period to find the study population of 174 patients, which were randomly assigned to receive erlotinib or platinum-based chemotherapy.

The response rate to erlotinib was 54.5%, compared with 10.5% to chemotherapy, according to preliminary results. Progression-free survival in the erlotinib arm was 9.4 months, compared with 5.2 months in the chemotherapy arm. Median survival was 22.9 months in the erlotinib arm and 18.8 months in the chemotherapy arm.

"Our results showed that first-line erlotinib nearly doubled progression-free survival; that's a significant improvement over chemotherapy, with a better tolerability profile," Dr. Gervais said. "We now have results for the use of first-line erlotinib in Asian and Western EGFR mutation-positive patients with NSCLC, and so we can carry this knowledge into our daily practice. I think EURTAC really is a big step towards individualized lung cancer care."


'/>"/>

Contact: Rene McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... ... pleased to announce the release of its 2017 update to Compass, the ... staff and physician advisors. , Suitable for standardizing both new-hire on-boarding and ...
(Date:3/1/2017)... ... 01, 2017 , ... Expert on international living and leading a healthy lifestyle, ... , Time & Go app is the ultimate strategic compass that helps users to ... methods enable people to work smarter, not harder, that's why Time & Go app ...
(Date:3/1/2017)... ... ... is Comfort for the Soul”: a loving account of a very special dog, the ... soul-healing comfort provided by God’s presence in the face of deep sorrow. “There is ... dog-loving medical professional whose work takes her to remote areas in the American Northwest, ...
(Date:3/1/2017)... ... ... Need of Obedience to the Law of God”: a message about the revelation of God ... the Law of God” is the creation of published author Brent Chrishon, a former sales ... children have since dedicated their lives to spreading God’s word both in the United States ...
(Date:2/28/2017)... ... February 28, 2017 , ... Answering strong demand for its medical device software ... a branch office in the Soma neighborhood in San Francisco on March 1, 2017. ... regulatory and software systems architecture subject matter experts. , Orthogonal serves a sizeable clientele ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... 1, 2017 The Thyroid Pharmacist, Dr. ... foremost authorities on the thyroid and thyroid conditions, as ... activism, has designed and launched a revolutionary new 9-part ... deeps into the realities of thyroid disease, dispelling the ... path to recovery.  Dr. Wentz, who graduated ...
(Date:3/1/2017)... MINNEAPOLIS , March 1, 2017 Bio-Techne ... -based DK Diagnostics to release its first diagnostic ... is an innovative parasitological system which contains the ... The PARATEST system will be manufactured at Bio-Techne,s ... site and leverages its state-of-art formulation, manufacturing, ...
(Date:3/1/2017)... , March 1, 2017  Integrated ... in the design and implementation of pre-fabricated ... and patient room headwalls, seeks to lead ... and higher-quality solutions. Fueled by ... products capable of reducing construction timelines and ...
Breaking Medicine Technology: